Berlin, Germany, and Athens, Greece – February 2026 – StratifAI, the AI biomarker company for precision oncology, today announced a partnership with the Hellenic Cooperative Oncology Group (HeCOG), a non-profit scientific society of leading pathologists and oncologists. Through this collaboration, StratifAI gains exclusive access to HeCOG’s data resources to validate StratifAI Polaris™, the company’s multimodal AI platform, as the foundation for developing novel biomarkers that enhance cancer diagnosis and prognosis.
Advancing cancer research through multimodal AI
At the core of this collaboration is the development of AI models capable of analyzing high-resolution histopathological images, specifically, hematoxylin and eosin (H&E)-stained slides, across multiple tumor types. By integrating computational pathology with clinical data from large-scale Phase III Randomized Controlled Trials, the collaboration aims to validate StratifAI Polaris™ as an evidence-based standard for cancer prognosis and treatment decision support.
A data-centric approach to precision oncology
The study will encompass large patient cohorts from Phase III clinical trials, applying state-of-the-art deep learning using StratifAI's proprietary large-scale foundation model and multimodal AI technology. These tools will be used to analyze the tumor biology at scale, modeling associations with patient outcomes in a fully end-to-end manner.
A global vision for cancer care
This partnership emphasizes the development of novel biomarkers which are deployable at scale, supporting the global effort to deliver better outcomes in oncology.
From detecting known molecular biomarkers from H&E slides, to directly predicting treatment response, the insights generated through this collaboration are intended to reach routine clinical use after thorough validation and certification.
In addition to breast cancer, the collaboration expands to ovarian cancer, further demonstrating the versatility of Polaris™ across multiple tumor types. With HeCOG’s expertise in clinical research and access to diverse patient populations, the work remains firmly grounded in real-world oncology practice. Together, StratifAI and HeCOG are committed to delivering tools that are both scientifically robust and practical for everyday clinical use.
